An Open-label, Multi-centre, Randomised, Parallel-group Trial, Comparing Efficacy and Safety of Degarelix One-month Dosing Regimen With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2016
At a glance
- Drugs Degarelix (Primary) ; Goserelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PANDA
- Sponsors Ferring Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 04 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.